Literature DB >> 17457031

Sigma receptor type 1 gene variation in a group of Polish patients with Alzheimer's disease and mild cognitive impairment.

Aleksandra Maruszak1, Krzysztof Safranow, Magdalena Gacia, Tomasz Gabryelewicz, Agnieszka Słowik, Maria Styczyńska, Beata Pepłońska, Maciej P Golan, Cezary Zekanowski, Maria Barcikowska.   

Abstract

The sigma-1 receptor (SIGMAR1) is a subtype of a nonopioid sigma receptor family and is implicated in numerous functions connected with Alzheimer's disease (AD). Two common genetic variants were identified in SIGMAR1: GC-241 -240TT and Q2P (A61C). It was suggested that the TT-C haplotype is a protective factor for AD. We decided to investigate a putative link between the variants of SIGMAR1 and AD in a group of Polish patients with late-onset AD, in patients with mild cognitive impairment, and in a control group. We observed no significant differences for the SIGMAR1 allele, genotype, haplotype, and diplotype distributions between the studied groups. Multivariate logistic regression analysis showed no interaction between the APOE4 and SIGMAR1 polymorphisms. Further studies using data from different populations are required to elucidate the effect of SIGMAR1 polymorphisms on AD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17457031     DOI: 10.1159/000101990

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  10 in total

Review 1.  Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Shang-Yi Tsai; Tomohisa Mori; Michiko Fujimoto; Tsung-Ping Su
Journal:  Expert Opin Ther Targets       Date:  2011-03-05       Impact factor: 6.902

Review 2.  Sigma-1 receptor chaperones in neurodegenerative and psychiatric disorders.

Authors:  Shang-Yi A Tsai; Michael J Pokrass; Neal R Klauer; Nicole E De Credico; Tsung-Ping Su
Journal:  Expert Opin Ther Targets       Date:  2014-10-21       Impact factor: 6.902

3.  The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease.

Authors:  Daniel Ryskamp; Jun Wu; Michal Geva; Rebecca Kusko; Iris Grossman; Michael Hayden; Ilya Bezprozvanny
Journal:  Neurobiol Dis       Date:  2016-11-03       Impact factor: 5.996

4.  Sigma-1 receptor regulates Tau phosphorylation and axon extension by shaping p35 turnover via myristic acid.

Authors:  Shang-Yi A Tsai; Michael J Pokrass; Neal R Klauer; Hiroshi Nohara; Tsung-Ping Su
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-11       Impact factor: 11.205

Review 5.  Roles of sigma-1 receptors in Alzheimer's disease.

Authors:  Jia-Li Jin; Min Fang; Yan-Xin Zhao; Xue-Yuan Liu
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 6.  The pharmacology of sigma-1 receptors.

Authors:  Tangui Maurice; Tsung-Ping Su
Journal:  Pharmacol Ther       Date:  2009-07-18       Impact factor: 12.310

Review 7.  The sigma-1 receptor: roles in neuronal plasticity and disease.

Authors:  Saïd Kourrich; Tsung-Ping Su; Michiko Fujimoto; Antonello Bonci
Journal:  Trends Neurosci       Date:  2012-10-23       Impact factor: 13.837

8.  Mutational Analysis of Sigma-1 Receptor's Role in Synaptic Stability.

Authors:  Daniel A Ryskamp; Vladimir Zhemkov; Ilya Bezprozvanny
Journal:  Front Neurosci       Date:  2019-09-19       Impact factor: 4.677

9.  Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor.

Authors:  Daniel Ryskamp; Lili Wu; Jun Wu; Dabin Kim; Gerhard Rammes; Michal Geva; Michael Hayden; Ilya Bezprozvanny
Journal:  Neurobiol Dis       Date:  2018-12-27       Impact factor: 5.996

10.  Evaluation of 18F-IAM6067 as a sigma-1 receptor PET tracer for neurodegeneration in vivo in rodents and in human tissue.

Authors:  François-Xavier Lepelletier; Matthias Vandesquille; Marie-Claude Asselin; Christian Prenant; Andrew C Robinson; David M A Mann; Michael Green; Elizabeth Barnett; Samuel D Banister; Marco Mottinelli; Christophe Mesangeau; Christopher R McCurdy; Inga B Fricke; Andreas H Jacobs; Michael Kassiou; Hervé Boutin
Journal:  Theranostics       Date:  2020-06-29       Impact factor: 11.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.